Method of producing a nucleic acid encoding an antibody

Details Method of producing a nucleic acid encoding an antibody Method of producing a nucleic acid encoding an antibody

2011-08-30

2011-08-30

Belyavskyi, Michail A (Department: 1644)

Chemistry: molecular biology and microbiology

Process of mutation, cell fusion, or genetic modification

Introduction of a polynucleotide molecule into or...

C435S326000, C435S252300, C536S023500

Reexamination Certificate

active

08008076

ABSTRACT:
An objective of the present invention is to facilitate the acquisition of antibody-producing cells that are infiltrating virus-infected cells, cancer cells, abnormal cells forming a benign hyperplasia, and the like, and to improve the efficiency of the production of antibodies as well as nucleic acids encoding them from the antibody-producing cells.The present inventors discovered that, when cancer tissues comprising infiltrating lymphocytes are transplanted into highly immunodeficient animals that do not have T cells, B cells, and NK cells and further exhibit a low IFN production ability, the differentiation and proliferation of infiltrating lymphocytes are unexpectedly promoted, and the number of plasma cells that produce antibodies recognizing cancer tissues increases dramatically, plasma cells can be separated easily, and antibodies or nucleic acids encoding them can be easily prepared from the plasma cells.

REFERENCES:
patent: 5495002 (1996-02-01), Kobrin et al.
patent: 2002/0193296 (2002-12-01), Xu et al.
patent: 2006/0235207 (2006-10-01), Tsuchiya et al.
patent: 0 236 637 (1987-09-01), None
patent: 6-141884 (1994-05-01), None
patent: WO 00/20460 (2000-04-01), None
patent: WO 01/68682 (2001-09-01), None
patent: WO 2004/048571 (2004-06-01), None
Williams et al J of Immunol. 1996, v.156, pp. 1908-1915.
Hansen et al., PNAS, 2001, v.98, pp. 12659-12664.
Coronella et al Cancer Research, 2001, v.61, pp. 7889-7899.
Owens et al J of Immunol Method , 1994, V.168, pp. 149-165.
Abe, “DNA o Mochiita Shuyo Tokuiteki Kogen ni Taisuru Men'eki Yudo B Saibosei Akusei Shuyo o Model ni,”Sankyo Seimei Kagaku Kenkyu Shinko Zaidan Kenkyu Hokokushu,11:213-219 (1998).
Coronella,Cancer Research, 61:7889-7899 (2001).
Hiramatsu et al., “Complete reconstitution of human lymphocytes from cord blood CD34+ cells using the NOD/SCID/gammacnull mice model,”Blood, 102(3):873-880 (2003).
Ichinomiya et al., “VII. Men'eki Saibo 2. Laser Microdissection o Riyo shita Men'eki Soshiki no Atarashii Kaisekiho,”Annual Review Men'eki 2002, pp. 174-179 (2001).
Jicha et al., “The Persistence of Human Peripheral Lymphocytes, Tumor Infiltrating Lymphocytes, and Colon Adenocarcinomas in Immunodeficient Mice,”J. Immunother., 11:19-29 (1992).
Kobari et al., “In vitro and in vivo evidence for the long-term multilineage (myeloid, B, NK, and T) reconstitution capacity of ex vivo expanded human CD34+cord blood cells,”Exp. Hematol., 28(12):1470-1480 (2000).
Koch et al.,American Journal of Pathology, 137(5):1199-1213 (1990).
Lubaroff et al., “Survival of Human Prostate Carcinoma, Benign Hyperplastic Prostate Tissues, and IL-2-Activated Lymphocytes in SCID Mice,”Prostate., 27:32-41 (1995).
Mallison et al.,Infection and Immunity, 59(11):4019-4025 (1991).
Obiakor et al.,Analytical Biochemistry, 306:55-62 (2002).
Plasma cell. In Webster's New World™ Medical Dictionary. Retrieved from the Internet on Feb. 27, 2008 at: http://www.credoreference.com/entry/2438767 (2003).
Tachikawa et al., “Laser Microdissection-ho no Gan Chiryo eno Oyo,”Hematology&Oncology, 42:565-571 (2001).
Walton et al., “Unrestricted usage of immunoglobulin heavy chain genes in B cells infiltrating the wall of atherosclerotic abdominal aortic aneurysms,”Atherosclerosis, 135:65-71 (1997).
Japanese Patent Office, International Search Report for App. Ser. No. JP2003/014919, mailed Jan. 13, 2004, 2 pages.
Japanese Patent Office, International Preliminary Report on Patentability for App. Ser. JP2003/014919, dated Apr. 1, 2004, 3 pages.
USPTO Non-Final Office Action in U.S. Appl. No. 10/535,764, dated Jul. 5, 2007, 10 pages.
Fish & Richardson P.C., Amendment in Reply to Action dated Jul. 5, 2007 in U.S. Appl. No. 10/535,764, filed Dec. 4, 2007, 8 pages.
USPTO Final Office Action in U.S. Appl. No. 10/535,764, dated Mar. 31, 2008, 16 pages.
Fish & Richardson P.C., Amendment in Reply to Action dated Mar. 31, 2008 in U.S. Appl. No. 10/535,764, filed Apr. 24, 2009, 14 pages.
USPTO Non-Final Office Action in U.S. Appl. No. 10/535,764, dated Jul. 24, 2009, 16 pages.
Japanese Patent Office International Search Report for App. Ser. No. JP2005/007962, mailed Jul. 12, 2005, 2 pages.
International Preliminary Report on Patentability for App. Ser. No. PCT/JP2005/007962, 6 pages.
European Search Report for App. Ser. No. EP 05 73 7209, dated Jan. 8, 2009, 5 pages.
Åman et al., “Epstein-Barr Virus Susceptibility of Normal Human B Lymphocyte Populations,”J. Exp. Med., 159:208-220 (1984).
Better et al., “Escherichia coliSecretion of an Active Chimeric Antibody Fragment,”Science, 240:1041-1043 (1988).
Bird et al., “Single-Chain Antigen-Binding Proteins,”Science, 242:423-426 (1988).
Bonner et al., “Laser Capture Microdissection: Molecular Analysis of Tissue”,Science, 278:1481-83 (1997).
Borsos, “Immunoglobulin Classes and Complement-Fixing Activity,” inProgress in Immunology, Academic Press, New York, pp. 841-848 (1971).
Brändlein et al., “Natural IgM Antibodies and Immunosurveillance Mechanisms Against Epithelial Cancer Cells in Humans,”Cancer Research, 63:7995-8005 (2003).
Brittenden et al., “Natural Killer Cells and Cancer,”Cancer, 77: 1226-1243 (1996).
Cerundolo et al., “Functional Activity in vivo of Effector T Cell Populations III. Protection Against Moloney Murine Sarcoma Virus (M-MSV)-Induced Tumors in T Cell Deficient Mice by the Adoptive Transfer of a M-MSV-Specific Cytolytic T Lymphocyte Clone,”Eur. J. Immunol., 17:173-178 (1987).
Chen et al., “A Testicular Antigen Aberrantly Expressed in Human Cancers Detected by Autologous Antibody Screening,”Proc. Natl. Acad. Sci. USA, 94: 1914-1918 (1997).
Coronella et al., “Antigen-Driven Oligoclonal Expansion of Tumor-Infiltrating B Cells in Infiltrating Ductal Carcinoma of the Breast”,J. Immunol., 169:1829-36 (2002).
Depraetere et al., “Human B Cell Growth and Differentiation in the Spleen of Immunodeficient Mice,”J. Immunol., 166: 2929-2936 (2001).
Donze et al., “Human and Nonhuman Primate Lymphocytes Engrafted Into SCID Mice Reside in Unique Mesenteric Lymphoid Structures,”J. Immunol., 161: 1306-1312 (1998).
Green et al., “Monoclonal Antibody Therapy for Solid Tumors,”Cancer Treatment Reviews, 26: 269-286 (2000).
Hanna, “Regulation of natural Killer Cell Activation: Implementation for the Control of Tumor Metastasis,”Nat. Immun. Cell Growth Reg., 3: 22-33 (1983-1984).
Hansen et al., “The tumor-infiltrating B cell response in medullary breast cancer is oligoclonal and directed against the autoantigen actin exposed on the surface of apoptotic cancer cells,”Proc. Natl. Acad. Sci. USA, 98:12659-12664 (2001).
Henderson et al., “Efficiency of Transformation of Lymphocytes by Epstein-Barr Virus,”Virology, 76:152-163 (1977).
Hurlimann et al., “Mononuclear Cells Infiltrating Human Mammary Carcinomas: Immunohistochemical Analysis with Monoclonal Antibodies,”Int. J. Cancer, 35:753-762 (1985).
Husby et al., “Tissue T and B Cell Infiltration of Primary and Metastatic Cancer,”J. Clin. Invest., 57:1471-1482 (1976).
Imahayashi et al., “Tumor-Infiltrating B-Cell-Derived IgG Recognizes Tumor Components in Human Lung Cancer,”Cancer Invest., 18: 530-536 (2000).
Ioachim, EMBASE Accession No. EMB-1977199257,J. Natl. Cancer Inst., 57:465-75 (1976).
Ito et al., “NOD/SCID/γcnullMouse: An Excellent Recipient Mouse Model for Engraftment of Human Cells,”Blood, 100: 3175-3182 (2002).
Kanashima et al., “SCID-hu Mouse—Hito Zoketsu Men'ekikei Kenkyu eno Oyo,”Taisya, 27: 149-154 (1990).
Kiyoi et al., “NOG Mouse eno Ishu Ishokukei o Mochiita Hito Saitaiketsu CD34 Yosei Saibo kara no B Saibo Bunka Katei no Kaiseki,”Mukin Seibutsu(Journal of Germfree Life and GnotoBiology), 33: 104-106 (2003) [English Abstract Pro

Affiliated with

Also associated with

Rating

Method of producing a nucleic acid encoding an antibody does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method of producing a nucleic acid encoding an antibody, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of producing a nucleic acid encoding an antibody will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2737939